Background and Aim: Higher rates of surgical delivery and maternal morbidity are linked to prolonged labour. A cervical spasmolytic drug called Hyoscine-N-butylbromide (Buscopan) may speed up labour by promoting cervical dilatation. This study assessed how intravenous Buscopan affected the length of labour and the outcomes for both the mother and the newborn in primigravida women.
Material and Methods: A randomised controlled trial with 120 primigravida women in active labour was carried out at SMGS Hospital, GMC Jammu. The trial group (n = 60) got 20 mg IV Buscopan at 4 cm cervical dilatation, while the control group (n = 60) did not receive any antispasmodic. Using the proper statistical tests, baseline features, maternal haemodynamics, adverse effects, newborn outcomes, cervical dilatation rate, stage-wise labour length, and mode of delivery were examined.
Results: Age, BMI, socioeconomic level, and gestational age were baseline characteristics that were similar among groups (p>0.05). The average duration of the active stage (189.87 vs. 298.89 min; p<0.001), second stage (24.59 vs. 29.84 min; p<0.001), and overall labour time (224.86 vs. 336.45 min; p<0.001) was all significantly decreased by Buscopan. In the study group, the cervical dilatation rate was almost twice (1.89 vs. 1.02 cm/hr). Both groups' third-stage duration and maternal haemodynamics were comparable. There was no significant difference in newborn outcomes, such as APGAR scores, birth weight, and NICU admissions, however dry mouth was more common with Buscopan (13.3% vs. 3.3%; p=0.048).
Conclusion: IV Buscopan given at a cervical dilation of 4 cm considerably reduces the length of labour without having a negative impact on the mother or the newborn. It serves as a secure and useful labour management adjunct.
International Journal of Clinical Obstetrics and Gynaecology
Indexed in Index Copernicus
Research Journals